4-[(3-fluorobenzyl)oxy]phenol

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 4-[(3-fluorobenzyl)oxy]phenol
• 英文别名: 4-(3-Fluorobenzyloxy)phenol；4-[(3-fluorophenyl)methoxy]phenol
• 化学式: C₁₃H₁₁FO₂
• mdl: MFCD11181736
• 分子量: 218.228
• InChiKey: FVGVXDMPESJXDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-[(3-fluorobenzyl)oxy]phenol 在 盐酸 、 三乙胺 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲醇 、 乙酸乙酯 为溶剂， 反应 24.5h， 生成 methyl 4-{4-[(3-fluorobenzyl)oxy]phenoxy}piperidine-1-carboxylate
  参考文献：
  名称：

  Synthesis and structure–activity relationships of benzyloxyphenyl derivatives as a novel class of NCX inhibitors: effects on heart failure

  摘要：

  In the context of heart failure and myocardial ischemia reperfusion, the activity of the sodium-calcium exchanger can lead to calcium overload, which in turn can lead to contractile dysfunction and arrhythmia. Therefore, NCX is an attractive target for treatment of heart failure and myocardial ischemia reperfusion. We have designed and synthesized a series of benzyloxyphenyl derivatives as potential NCX inhibitors, based on compound 4. These derivatives have been evaluated for their inhibitory activity against both the reverse and forward modes of NCX, and two novel potent NCX inhibitors (7i, 10a) were discovered. Compound 7i was evaluated for its efficacy on ouabain-induced tonotropy and arrhythmia in a heart-failure model. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.10.048

文献信息

• Benzyloxy derivatives as MAOB inhibitors
  申请人：Jolidon Synese

  公开号：US20050288367A1

  公开（公告）日：2005-12-29

  The invention relates to compounds of the formula and their pharmaceutically acceptable salts wherein R 1 , R 2 , R 3 , R 4 , R 5 , n, m, and o are as defined in the specification. The compounds are selective monoamine oxidase β inhibitors and are useful for the treatment and prevention of Alzheimer's disease and senile dementia, as well as other CNS disorders. The invention also relates to processes for preparing such compounds and pharmaceutical compositions containing them.

  这项发明涉及以下公式的化合物及其药学上可接受的盐，其中R1、R2、R3、R4、R5、n、m和o如规范中所定义。这些化合物是选择性单胺氧化酶β抑制剂，对治疗和预防阿尔茨海默病和老年性痴呆症以及其他中枢神经系统疾病有用。该发明还涉及制备这类化合物的方法和含有它们的药物组合物。
• [EN] BICYCLIC DERIVATIVES AS PPAR MODULATORS<br/>[FR] DERIVES BICYCLIQUES EN TANT QUE MODULATEURS DE PPAR
  申请人：LILLY CO ELI

  公开号：WO2005066136A1

  公开（公告）日：2005-07-21

  The present invention is directed to compounds represented by the following structural formula, Formula (I), and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: (a) R2 is selected from the group consisting of C0-C8 alkyl and C1-4- heteroalkyl; (b) X is selected from the group consisting of a single bond, O, S, S(O)2 and N; (c) U is an aliphatic linker wherein one carbon atom of the aliphatic linker is optionally replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with from one to four substituents each independently selected from R30; (d) Y is selected from the group consisting of C, O, S, NH and a single bond; and (e) E is C(R3)(R4)A or A.

  本发明涉及由以下结构公式（I）表示的化合物，以及它们的立体异构体、药用可接受的盐、溶剂化物和水合物，其中：(a) R2 是由C0-C8烷基和C1-4-杂烷基组成的组中选出的；(b) X 是由单个键、O、S、S(O)2和N组成的组中选出的；(c) U 是一个脂肪族连接链，其中脂肪族连接链的一个碳原子可选地被O、NH或S替换，并且这样的脂肪族连接链可被选自R30的一个到四个取代基独立地取代；(d) Y 是由C、O、S、NH和单个键组成的组中选出的；以及(e) E 是C(R3)(R4)A或A。
• [EN] FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS<br/>[FR] DERIVES HETEROCYCLIQUES FUSIONNES UTILISES EN TANT QUE MODULATEURS PPAR
  申请人：LILLY CO ELI

  公开号：WO2004063155A1

  公开（公告）日：2004-07-29

  The present invention is directed to compounds represented by the following structural formula, Formula I: wherein (a) X is selected from the group consisting of a single bond, O, S. S(O)2 and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of C, O, S, NH and a single bond; (d) E is C(R3) (R4)A or A and wherein (i) A is selected from the group consisting of carboxyl, tetrazole, C1-C6 alkylnitrile, carboxamidek, sulfonamide and acylsulfonamide; (e) B is selected from the group consisting of S, O, C, and N; (f) Z is selected from the group consisting of N and C; with the proviso that when B is C then Z is N.

  本发明涉及由以下结构式I表示的化合物：其中（a）X选自单键、O、S、S（O）2和N组成的群；（b）U是脂肪链连接物；（c）Y选自C、O、S、NH和单键组成的群；（d）E是C（R3）（R4）A或A，其中（i）A选自羧基、四唑基、C1-C6烷基腈、羧酰胺、磺酰胺和酰基磺酰胺组成的群；（e）B选自S、O、C和N组成的群；（f）Z选自N和C组成的群；但当B为C时，则Z为N。
• [EN] PPAR MODULATORS<br/>[FR] MODULATEURS DU RECEPTEUR ACTIVE DE LA PROLIFERATION DES PEROXYSOMES (PPAR)
  申请人：LILLY CO ELI

  公开号：WO2005019151A1

  公开（公告）日：2005-03-03

  The present invention is directed to a compound of formula I, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

  本发明涉及一种具有式I的化合物，或其药学上可接受的盐、溶剂合物、水合物或立体异构体，该化合物在治疗或预防由过氧化物酶体增殖物激活受体（PPAR）介导的疾病中具有用途，如X综合征、2型糖尿病、高血糖、高脂血症、肥胖、凝血障碍、高血压、动脉硬化以及与X综合征和心血管疾病相关的其他疾病。
• Discovery of N-(3-{4-[(3-Fluorobenzyl)oxy]phenoxy}propyl)-2-pyridin-4-ylacetamide as a Potent and Selective Reverse NCX Inhibitor
  作者：Takahiro Kuramochi、Akio Kakefuda、Hiroyoshi Yamada、Takashi Ogiyama、Taku Taguchi、Shuichi Sakamoto

  DOI：10.1248/cpb.53.1043

  日期：——

  In the setting of heart failure and myocardial ischemia-reperfusion, the sodium–calcium exchanger (NCX) can lead to calcium overload, which is responsible for contractile dysfunction and arrhythmia. NCX is an attractive target for treatment in heart failure and myocardial ischemia-reperfusion. We have designed and synthesized a series of benzyloxyphenyl derivatives based on compound 3. These derivatives have been evaluated for their inhibitory activity against both the reverse and forward modes of NCX. We have discovered a novel potent and selective reverse NCX inhibitor (12) with an IC50 value of 0.085 μM against reverse NCX.

  在心力衰竭和心肌缺血再灌注的情况下，钠钙交换机（NCX）会导致钙超载，从而引起收缩功能障碍和心律失常。NCX 是治疗心力衰竭和心肌缺血再灌注的一个有吸引力的靶点。我们以化合物 3 为基础，设计并合成了一系列苄氧基苯基衍生物。我们评估了这些衍生物对 NCX 反向和正向模式的抑制活性。我们发现了一种新型强效选择性反向 NCX 抑制剂 (12)，其对反向 NCX 的 IC50 值为 0.085 μM。